Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Linyi, China Clinical Trials

A listing of Linyi, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (7) clinical trials

Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC

This is a randomized, open-label, multicenter Phase 3 study in adult patients with histologically confirmed, locally advanced or metastatic (Stage IIIB or IV), NSCLC (squamous or non-squamous) who have disease progression during or after a platinum-containing regimen.

Phase

0.0 miles

Learn More »

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of BGB-A317 as second line treatment in patients with advanced unresectable/metastatic ESCC that has progressed during or after first line therapy.

Phase

0.0 miles

Learn More »

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

This is a Phase III clinical study, which aims to compare the efficacy and safety of BPI-7711 capsule and gefitinib tablet in the treatment of initially-treated patients with locally advanced or recurrent metastatic with EGFR mutation.

Phase

0.0 miles

Learn More »

Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

This is a regional, multicentre, randomized, double-blind, placebo controlled, parallel group, phase 3 study designed to evaluate the efficacy and safety of 210 mg Q4W (SC) of tezepelumab in adults with severe, uncontrolled asthma on medium to high-dose ICS and at least one additional asthma controller medication with or without ...

Phase

3.4 miles

Learn More »

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma

This is a randomized (1:1), double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab or placebo plus chemotherapy as first-line (1L) therapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Phase

3.69 miles

Learn More »

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Adult patients with a histologically or cytologically documented metastatic NSCLC, with tumors that lack activating EGFR mutations and ALK fusions, are eligible for enrollment. Patients will be randomized in a 1:1:1 ratio to receive treatment with durvalumab + tremelimumab combination therapy + SoC chemotherapy, durvalumab monotherapy + SoC chemotherapy, or ...

Phase

6.69 miles

Learn More »

Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC

Lung cancer is the leading cause of cancer-related mortality worldwide. A report published by the WHO in February 2014, estimated there were 1.83 million new cases and 1.59 million deaths worldwide in 2012. The American Lung Association reports 399,431 Americans living with lung cancer, with an estimated 221,200 new cases ...

Phase

6.78 miles

Learn More »